Đang chuẩn bị liên kết để tải về tài liệu:
FemZone trial: A randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients
Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
The objective of this prospectively randomized phase II trial (Trial registration: EUCTR2004-004007-37-DE) was to compare the clinical response of primary breast cancer patients to neoadjuvant therapy with letrozole alone (LET) or letrozole and zoledronic acid (LET + ZOL). |